HOOKIPA PHARMA INC (HOOK)
US43906K1007 - Common Stock
We assign a fundamental rating of 4 out of 10 to HOOK. HOOK was compared to 586 industry peers in the Biotechnology industry. While HOOK seems to be doing ok healthwise, there are quite some concerns on its profitability. HOOK is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year HOOK has reported negative net income.
HOOK had a negative operating cash flow in the past year.
HOOK had negative earnings in each of the past 5 years.
HOOK had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of -32.58%, HOOK is doing good in the industry, outperforming 67.52% of the companies in the same industry.
With a decent Return On Equity value of -45.47%, HOOK is doing good in the industry, outperforming 70.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.58% | ||
| ROE | -45.47% | ||
| ROIC | N/A |
ROA(3y)-49.57%
ROA(5y)-40.42%
ROE(3y)-79.53%
ROE(5y)-60.66%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HOOK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
HOOK does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HOOK has been increased compared to 1 year ago.
HOOK has more shares outstanding than it did 5 years ago.
HOOK has a better debt/assets ratio than last year.
2.2 Solvency
HOOK has an Altman-Z score of -2.18. This is a bad value and indicates that HOOK is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.18, HOOK perfoms like the industry average, outperforming 48.21% of the companies in the same industry.
HOOK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.18 |
ROIC/WACCN/A
WACC8.87%
2.3 Liquidity
HOOK has a Current Ratio of 4.50. This indicates that HOOK is financially healthy and has no problem in meeting its short term obligations.
HOOK has a Current ratio (4.50) which is comparable to the rest of the industry.
A Quick Ratio of 4.50 indicates that HOOK has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.50, HOOK is in line with its industry, outperforming 48.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.5 | ||
| Quick Ratio | 4.5 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 45.65% over the past year.
The Revenue has grown by 234.93% in the past year. This is a very strong growth!
The Revenue has been growing by 21.41% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)45.65%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q140.74%
Revenue 1Y (TTM)234.93%
Revenue growth 3Y0.93%
Revenue growth 5Y21.41%
Revenue growth Q2Q1052.36%
3.2 Future
HOOK is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.92% yearly.
HOOK is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 58.43% yearly.
EPS Next Y58.56%
EPS Next 2Y18.57%
EPS Next 3Y7.51%
EPS Next 5Y15.92%
Revenue Next Year74.88%
Revenue Next 2Y-10.91%
Revenue Next 3Y-32.32%
Revenue Next 5Y58.43%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for HOOK. In the last year negative earnings were reported.
Also next year HOOK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.57%
EPS Next 3Y7.51%
5. Dividend
5.1 Amount
HOOK does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HOOKIPA PHARMA INC
NASDAQ:HOOK (5/17/2024, 7:04:22 PM)
After market: 0.8184 +0 (+0.37%)0.8154
+0 (+0.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap78.73M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.58% | ||
| ROE | -45.47% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.5 | ||
| Quick Ratio | 4.5 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)45.65%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y58.56%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)234.93%
Revenue growth 3Y0.93%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y